Towards an effective genital herpes vaccine: Past lessons and future prospects

Future Virology

Volumn 2, Issue 1, 2007, Pages 1-6

  Halford, William P ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CELL PROTEIN; GLYCOPROTEIN D; GLYCOPROTEIN E; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS PROTEIN; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PENICILLIN G; PROTEIN C; PROTEIN HSV1; PROTEIN HSV2; PROTEIN ICP0; PROTEIN ICP34.5; PROTEIN ICP47; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CLONAL VARIATION; CLONOGENESIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOGENICITY; ITALY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SEXUAL TRANSMISSION; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VIRUS ACTIVATION; VIRUS EXPRESSION; VIRUS REPLICATION; VIRUS VIRULENCE;

HERPES;

EID: 34249313375     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.1.1     Document Type: Editorial

References (39)

1. Bernstein DI: Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 8, 8-11 (2001).
2. Cunningham AL, Mikloska Z: The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 8(Suppl. 1), A6-A10 (2001).
3. Pollara G, Karz DR, Chain BM: The host response to herpes simplex virus infection. Curr. Opin. Infect. Dis. 17, 199-203 (2004).
4. Toka FN, Pack CD, Rouse BT: Molecular adjuvants for mucosal immunity. Immunol. Rev. 199, 100-112 (2004).
5. Zimmerman DH, Rosenthal KS: The L.E.A.P.S. approach to vaccine development. Front Biosci. 10, 790-798 (2005).
6. Stanberry LR, Cunningham AL, Mindel A et al.: Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 30, 549-566 (2000).
7. Stanberry LR, Spruance SL, Cunningham AL: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661 (2002).
8. Stephenson J: Genital herpes vaccine shows limited promise. JAMA 284, 1913-1914 (2000).
9. Connor RI, Korber BT, Graham BS: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552-1576 (1998).
10. Tramont EC, Johnston MI: Progress in the development of an HIV vaccine. Expert Opin. Emerg. Drugs 8, 37-452 (2003).
11. Zolla-Pazner S: Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4, 199-210 (2004).
12. Skinner GR, Fink C, Melling J et al.: Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med. Microbiol. Immunol. (Berl.) 180, 305-320 (1992).
13. Skinner GR, Turyk ME, Benson CA et al.: The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med. Microbiol. Immunol. (Berl.) 186, 31-36 (1997).
14. Boursnell ME, Entwisle C, Blakeley D et al.: A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175, 16-25 (1997).
15. Da Costa XJ, Jones CA, Knipe DM: Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl Acad. Sci. USA 96, 6994-6998 (1999).
16. Dudek T, Knipe DM: Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239 (2006).
17. Morrison LA, Da Costa XJ, Knipe DM: Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243, 178-87 (1998).
18. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J: Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 99, 1092-1097 (1997).
19. Wald A, Zeh J, Selke S et al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 342, 844-850 (2000).
20. Buddingh GJ, Schrum DI, Lanier JC, Guidry DJ: Studies of the natural history of herpes simplex virus infections. Pediatrics 11, 593-605 (1953).
21. Kinghorn GR: Epidemiology of genital herpes. J. Int. Med. Res. 22, A14-A23 (1994).
22. Scott DA, Coulter WA, Lamey PJ: Oral shedding of herpes simplex virus type 1: a review. J. Oral Pathol. Med. 26, 441-447 (1997).
23. Halford WP, Weisend C, Grace J et al.: ICP0 antagonizes Star 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 3, 44 (2006).
24. Harle P, Sainz B Jr, Carr DJ, Halford WP: The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-α/β. Virology 293, 295-304 (2002).
25. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW: Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189, 663-672 (1999).
26. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW: Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl Acad Sci. USA 97, 6097-6101 (2000).
27. Mossman KL, Saffran HA, Smiley JR: Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J. Virol. 74, 2052-2056 (2000).
28. Mossman KL, Smiley JR: Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J. Virol. 76, 1995-1998 (2002).
29. Lubinski JM, Wang L, Soulika. AM et al.: Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72, 8257-8263 (1998).
30. Nagashunmugam T, Lubinski J, Wang L et al.: In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72, 5351-5359 (1998).
31. Hill A, Jugovic P, York I: Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415 (1995).
32. + T lymphocytes. Cell 77, 525-535 (1994).
33. Khanna KM, Lepisto AJ, Hendricks RL: Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol. 25, 230-234 (2004).
34. Koelle DM, Corey L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16, 96-113 (2003).
35. Morrison LA: Vaccines against genital herpes: progress and limitations. Drugs 62, 1119-1129 (2002).
36. Whitley RJ, Roizman B: Herpes simplex viruses: is a vaccine tenable? J. Clin. Invest. 110, 145-151 (2002).
37. + are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. 68, 48-55 (1994).
38. Davison AJ: Evolution of the herpesviruses. Vet. Microbiol. 86, 69-88 (2002).
39. Orr MT, Edelmann KH, Vieira J, Corey L, Raulet DH, Wilson CB: Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice. PLoS Pathog. 1, E7 (2005).